title: Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis.
abstract: The effectiveness of disease-modifying drugs in the treatment of multiple sclerosis is associated with adherence. RebiSmart® electronic device provides useful information about adherence to the treatment with subcutaneous (sc) interferon (IFN) β-1a (Rebif®). The aim of the study was to determine long-term adherence to this treatment in patients with relapsing-remitting multiple sclerosis (RRMS). This retrospective multicentre observational study analysed 258 patients with RRMS who were receiving sc IFN β-1a (Rebif®) treatment by using RebiSmart® until replacement (36 months maximum lifetime) or treatment discontinuation. Adherence was calculated with data (injection dosage, time, and date) automatically recorded by RebiSmart®. Patients in the study had a mean age of 41 years with a female proportion of 68%. Mean EDSS score at start of treatment was 1.8 (95% CI, 1.6-1.9). Overall adherence was 92.6% (95% CI, 90.6-94.5%). A total of 30.2% of patients achieved an adherence rate of 100%, 80.6% at least 90%, and only 13.2% of patients showed a suboptimal adherence (<80%). A total of 59.9% of subjects were relapse-free after treatment initiation. Among 106 subjects (41.1%) who experienced, on average, 1.4 relapses, the majority were mild (40.6%) or moderate (47.2%). Having experienced relapses from the beginning of the treatment was the only variable significantly related to achieving an adherence of at least 80% (OR = 3.06, 1.28-7.31). Results of this study indicate that sc IFN β-1a administration facilitated by RebiSmart® could lead to high rates of adherence to a prescribed dose regimen over 36 months.
authors.affiliation: Hospitales Universitarios Regional de Málaga y Virgen de la Victoria, Universidad de Málaga, IBIMA.
authors.forename: O
authors.initials: O
authors.lastname: Fernández
authors.affiliation: Hospital U. Clínico San Carlos, Madrid.
authors.forename: R
authors.initials: R
authors.lastname: Arroyo
authors.affiliation: Hospital Universitario de Bellvitge, Barcelona.
authors.forename: S
authors.initials: S
authors.lastname: Martínez-Yélamos
authors.affiliation: Corporació Sanitaria Parc Taulí, Barcelona.
authors.forename: M
authors.initials: M
authors.lastname: Marco
authors.affiliation: Hospital Universitario Puerta de Hierro, Madrid.
authors.forename: J A García
authors.initials: JA
authors.lastname: Merino
authors.affiliation: Hospital Xeral Cies, Vigo.
authors.forename: D
authors.initials: D
authors.lastname: Muñoz
authors.affiliation: Departamento Médico, Merck S.L.
authors.forename: E
authors.initials: E
authors.lastname: Merino
authors.affiliation: Departamento Médico, Merck S.L.
authors.forename: A
authors.initials: A
authors.lastname: Roque
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007267:Injections / Q000295:instrumentation*; D016899:Interferon-beta / Q000008:administration & dosage* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D012189:Retrospective Studies; D013997:Time Factors; D016903:Drug Monitoring
chemical_list: D016899:Interferon-beta